Market News AIOpen the app

Truist raised its price target for Teladoc Health from $8 to $9 while keeping a 'Hold' rating.

OpinionRead the original at marketscreener.com
Neutral

Truist raised its Teladoc Health target from $8 to $9 but kept its Hold rating. The story reports no new change in Teladoc's business, so it does not shift the company's outlook.

TDOC · Teladoc Health

AI read · Neutral

The AI's read

The target change reflects one firm's view, not a new report about Teladoc's business. Truist kept its Hold rating, and the story gives no new company results or business changes. Those facts leave no clear change in the company's outlook.

Get alerts for TDOC

Follow Teladoc Health (TDOC) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TDOC
Free on the App Store and Google Play, or on the web.